Community Oriented Tool for Reducing Melanoma Health Disparities

减少黑色素瘤健康差异的面向社区的工具

• 批准号: 8303053
• 负责人: Eric R. Craine
• 金额: $ 19.64万
• 依托单位: WESTERN RESEARCH COMPANY, INC.
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-01 至 2013-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8303053
• 关键词: Address; Affect; Archives; Awareness; Biopsy; Communities; Data; Data Collection; Development; Digital Photography; Disease; Early Diagnosis; Education; Education and Outreach; Evaluation; Foundations; Frequencies; Goals; Grant; Hand; Health; Healthcare; Hispanics; Home environment; Image; Imaging technology; Insurance; Language; Lesion; Literature; Malignant Neoplasms; Manuscripts; Medical; Mole the mammal; Outcome; Patients; Phase; Physicians; Pigments; Population; Preparation; Process; Protocols documentation; Public Health; Qualitative Research; Research; Resources; Risk; Screening procedure; Self Perception; Skin; Staging; System; Technology; Translations; United States National Center for Health Statistics; United States National Institutes of Health; combat; compliance behavior; efficacy evaluation; efficacy research; follow-up; health disparity; improved; innovation; melanoma; mortality; programs; tool

DESCRIPTION (provided by applicant): Melanoma is a frequently fatal cancer that, if detected early, is relatively easily cured. This disease is rapidly increasing in frequency and has recently been identified by the National Center for Health Statistics Health Disparities Study as a high profile health disparity. Further it has been noted to occur more frequently now in both young people and Hispanic populations. We have developed a unique, proprietary and innovative self-screening imaging technology (DermAlert) that has the potential to significantly mitigate disparate melanoma outcomes by more fully involving people at-risk of melanoma in their own healthcare, and by enabling much earlier detection of new and changed pigmented lesions that may be early melanomas. The goal of this NIH grant program is to address key issues (patient related causes for the disparity and physician/insurance requirements for efficacy demonstration) for the translation of this technology into the at- risk community to realize reduction in melanoma disparity. We propose a program to research the efficacy of DermAlert imaging self screening for new and changed pigmented lesions, and to provide education that will be useful in overcoming barriers to use of the DermAlert system in affected populations. Phase I activities will include: " Conversion of DermAlert to a Spanish language resource, " Analysis of specific classes of barriers to use of imaging by groups suffering melanoma health disparities, " Development of education and outreach tools to help overcome barriers to use of self imaging screening, " Preliminary evaluation of the effect of DermAlert use on health outcomes, and " Preparation for an expanded, large scale efficacy study during Phase II. As pigmented lesions, for which change was detected by the imaging system, are biopsied, the results of those biopsies will be tabulated and statistically compared with control set of biopsies for which imaging was not a motivating factor. Using this approach it will be possible to investigate not only patient compliance in the use of the imaging system, but also its utility in helping to guide more effective biopsy decisions. This part of the project will address its efficacy and the resultant medical outcomes Measureable milestones during Phase I include the following, which can be used to help assess the viability of progressing to Phase II research: " Qualitative and quantitative identification of specific barriers to imaging that contribute to the health disparity " Preparation of an educational video for helping patients and physicians overcome barriers to use of this technology, and " Foundation and preliminary analysis of an archive of follow-up biopsy data for evaluation of efficacy of using DermAlert. Successful completion of the project will result in enhanced awareness and reduced barriers to use of a completely unique imaging protocols which will more deeply involve patients in their personal health care, contribute to earlier detection of potential melanomas, and have the power to ultimately reduce the number of unnecessary biopsies and reduce patient mortality at the hands of a serious health disparity.

描述（由申请人提供）：黑色素瘤是一种经常致命的癌症，如果及早发现，相对容易治愈。这种疾病的发病率正在迅速增加，最近被国家卫生统计中心健康差异研究确定为引人注目的健康差异。此外，人们注意到这种情况现在在年轻人和西班牙裔人群中更频繁地发生。 我们开发了一种独特、专有和创新的自我筛查成像技术 (DermAlert)，通过更充分地让有黑色素瘤风险的人参与自己的医疗保健，并通过更早地检测新的黑色素瘤，有可能显着减轻不同的黑色素瘤结果。改变的色素病变可能是早期黑色素瘤。该 NIH 拨款计划的目标是解决关键问题（与患者相关的差异原因以及疗效证明的医生/保险要求），以便将该技术转化为高危人群，以实现黑色素瘤差异的减少。 我们提出了一项计划，研究 DermAlert 成像自我筛查对新的和改变的色素病变的功效，并提供有助于克服受影响人群使用 DermAlert 系统障碍的教育。 第一阶段的活动将包括：“将 DermAlert 转换为西班牙语资源，”分析患有黑色素瘤健康差异的群体使用成像的具体障碍，“开发教育和推广工具以帮助克服使用自我成像的障碍筛选，“初步评估 DermAlert 使用对健康结果的影响，以及”为第二阶段扩大、大规模功效研究做准备。当色素病变（通过成像系统检测到其变化）进行活检时，将得出以下结果：这些活检将被制成表格，并与成像不是激励因素的对照活检组进行统计比较。使用这种方法，不仅可以调查患者使用成像系统的依从性，还可以调查其在帮助治疗方面的效用。指导更有效的活检决策。该项目的这一部分将讨论其功效和由此产生的医疗结果第一阶段的可衡量里程碑包括以下内容，可用于帮助评估进入第二阶段研究的可行性：“定性和定量识别具体的导致健康差异的成像障碍“准备教育视频以帮助患者和医生克服使用该技术的障碍，以及”对后续活检数据档案进行基础和初步分析，以评估使用 DermAlert 的功效。 该项目的成功完成将提高人们的认识并减少使用完全独特的成像方案的障碍，这将更深入地让患者参与个人医疗保健，有助于及早发现潜在的黑色素瘤，并有能力最终减少黑色素瘤的数量。减少不必要的活检，并降低严重健康差距造成的患者死亡率。